Actavis is shelling out £306 million to snap up generic drugmaker Auden Mckenzie, hot on the heels of its whopping $66-billion-deal to buy Allergan.

The Dublin, Ireland-based group says the move will make it the number one supplier of generic pharmaceuticals in the UK and, after the close of the Allergan deal, number three in the supply of UK pharmaceuticals.  

The acquisition, which is still subject to certain conditions, is expected to close in the first quarter of next year, and be immediately accretive to Actavis’ non-GAAP earnings in 2015, the firm said. 

“This strategic combination is highly synergistic with our UK business, is immediately and highly accretive and reflects our commitment to invest to achieve a top position in key international markets,” noted Robert Stewart, Actavis’ chief operating officer.  

Since January last year, Actavis’ spending spree has seen it purchase Aptalis for about $2.90 billion, Forest Laboratories for $25 billion, Durata for $675 million and Actavis for $66 billion.